Principal Investigator(s):Laura Guay, MD, Francis Mmiro, MBChB, FRCOG
Objective:The purpose of this study is to test the safety of and immune response to an HIV-1 vaccine, ALVAC-HIV vCP1521, given to infants born to HIV-1 infected mothers in Uganda. Results: HIV-1 exposed infants are capable of generating low levels of cellular immune responses to ALVAC vaccine, similar to responses seen in adults.
Prevention Option(s):HIV Vaccine
Study Design:Double-blind, Randomized
Arms and Assigned Interventions
DescriptionOne 1-ml dose of HIV-1 vaccine administered after birth on or before Day 3 and at weeks 4, 8, and 12.
Mode of Delivery
Official Code: NCT00098163
Trial Sponsors: NIAID, NICHD, NIDA, NIMH
May 1, 2009
Age range: 18 Years ↔ any